M Pharmaceutical Rebrands Under the Mantra "Better Health. Better Life" to Highlight Obesity & Diabetes Technologies - Video News Alert on Investmentpitch.com

Vancouver, British Columbia--(Newsfile Corp. - July 20, 2015) - M Pharmaceutical (CSE: MQ) (OTCQB: MPHMF) (FSE: T3F1) has rebranded itself under the mantra "Better Health. Better Life." The company is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes.

InvestmentPitch.com has produced a "video news alert" which discusses the company and this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "M Pharmaceutical" in the search box.

The rebranding is designed to provide greater understanding of the company's emerging family of biomedical technologies, which are linked by the common "M" embedded in a stylized Circle of Life. The corporate brand mark and all product marks will share the common M in a colour-coded protocol that will be consistently applied across all communications platforms. Joining the eMosquito Wearable Blood Monitor will be Trimeo Weight Loss Capsules and the Trimtec Gastric Stimulation System.

Dr. Martin Mintchev, President & CEO stated: "Our new approach and communications platform will help us in our pursuit of excellence in the biomedical technologies that we believe will make a palpable difference in the lives of people living with obesity and diabetes. The rebranding simplifies the comprehensive vision of M Pharmaceutical, Inc. and crystalizes the story behind the eMosquito. In introducing Trimeo and Trimtec to our family, it represents an exciting new chapter in the growth and development of our company."

The company is currently undertaking a non-brokered private placement of up to $350,000, through the issuance of up to 3,888,888 units at $0.09 per unit, with each unit consisting of one common share and one share purchase warrant exercisable for one year at $0.25. The shares currently trade at $0.09.

On June 24th, New York based SeeThruEquity initiated coverage on M Pharmaceutical. Analyst Amit Tandon gave M-Pharma a target price of $0.79, a premium of 316% to the $0.19 price the day the report was issued.

George Tsafalas, a member of the Board of Directors added: "Based on the quality of people who have joined with Dr. Mintchev on our leadership team, our Board and our Advisory group, and given the progress the team has made on all fronts, we believed it was the right time to usher in our new look and feel."

For more information about M-Pharma, please visit the company's website www.m-pharma.ca, call 604-428-0511 or email info@m-pharma.ca.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com